HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus.

Abstract
The lytic DNA replication of Kaposi's sarcoma-associated herpesvirus (KSHV) initiates at an origin (ori-Lyt) and requires trans-acting elements, both viral and cellular. We recently demonstrated that several host cellular proteins, including topoisomerases I and II (Topo I and II), are involved in KSHV lytic DNA replication (Y. Wang, H. Li, Q. Tang, G. G. Maul, and Y. Yuan. J. Virol. 82: 2867-2882, 2008). To assess the importance of these topoisomerases in viral lytic replication, shRNA-mediated gene silencing was used. Depletion of Topo I and II severely inhibited viral lytic DNA replication as well as virion production, suggesting essential roles of these cellular proteins in viral DNA replication. The discovery of Topo I and II as enzymes indispensable for KSHV DNA replication raises a possibility that these cellular proteins could be new targets of therapeutic approaches to halt KSHV replication and treat KSHV-associated diseases. In this report, we examined one Topo I inhibitor and several Topo II inhibitors (inclusive of Topo II poison and catalytic inhibitors) as potential therapeutic agents for blocking KSHV replication. The Topo II catalytic inhibitors in general exhibited marked inhibition on KSHV replication and minimal cytotoxicity. In particular, novobiocin, with the best selectivity index (SI = 31.62) among the inhibitors tested in this study, is effective in inhibiting KSHV DNA replication and virion production but shows little adverse effect on cell proliferation and cycle progression in its therapeutic concentration, suggesting its potential to become an effective and safe drug for the treatment of human diseases associated with KSHV infection.
AuthorsLorenzo González-Molleda, Yan Wang, Yan Yuan
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 56 Issue 2 Pg. 893-902 (Feb 2012) ISSN: 1098-6596 [Electronic] United States
PMID22106228 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Neoplasm
  • Antiviral Agents
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • RNA, Small Interfering
  • Novobiocin
  • DNA Topoisomerases, Type I
  • TOP1 protein, human
  • DNA Topoisomerases, Type II
  • Camptothecin
Topics
  • Antigens, Neoplasm (drug effects, genetics, metabolism)
  • Antiviral Agents (pharmacology)
  • Camptothecin (pharmacology)
  • Cell Line
  • DNA Replication (drug effects)
  • DNA Topoisomerases, Type I (drug effects, genetics, metabolism)
  • DNA Topoisomerases, Type II (drug effects, genetics, metabolism)
  • DNA-Binding Proteins (drug effects, genetics, metabolism)
  • Enzyme Inhibitors (pharmacology)
  • Gene Silencing
  • Herpesvirus 8, Human (drug effects, genetics, physiology)
  • Humans
  • Novobiocin (pharmacology)
  • RNA, Small Interfering (genetics, metabolism)
  • Virion (metabolism)
  • Virus Replication (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: